No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DGX240719C135000
- 13.31
- +2.36+21.55%
15min DelayClose Jul 16 15:59 ET
13.31High12.44Low
12.44Open10.95Pre Close6 Volume18 Open Interest135.00Strike Price7.64KTurnover0.00%IV-0.20%PremiumJul 19, 2024Expiry Date13.60Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma10.97Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Quest Diagnostics Is Maintained at Hold by Truist Securities
Quest Diagnostics Is Maintained at Hold by Truist
Quest Diagnostics Price Target Raised to $158.00/Share From $150.00 by Truist Securities
Quest Diagnostics Price Target Raised to $158.00/Share From $150.00 by Truist
Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $158
Truist Financial analyst David S Macdonald maintains $Quest Diagnostics(DGX.US)$ with a hold rating, and adjusts the target price from $145 to $158.According to TipRanks data, the analyst has a
Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services
Truist Securities Adjusts Price Target on Quest Diagnostics to $158 From $150, Maintains Hold Rating
Quest Diagnostics (DGX) has an average outperform rating and a price target range of $136 to $165, according to analysts polled by Capital IQ.
Is Quest Diagnostics Incorporated (DGX) an Undervalued High Growth Stock?
Comments
$Quest Diagnostics(DGX.US$ PathAI + Invigorate + stable finance + qualified management team + decent PE.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
4
Quest Diagnostics' consistent ROCE and increased capital employed over the past five years suggest steady reinvestment at good returns. This trend, reflected in the stock's strong performance, is expected to continue.
The acquisition aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions and expands its ability to serve providers and patients in Ohio and Pennsylvania.
The CEO of Quest Diagnostics, Jim Davis, believes Yuri Fesko's deep medical expertise and patient-care advocacy will greatly contribute to the company's strategic decisions. His appointment especially bolsters Quest's efforts to improve customer experiences via diagnostic innovations.
Quest Diagnostics shows favorable metrics with robust reinvestment strategies. Significant earnings growth and an anticipated rise in future ROE, despite a higher payout ratio, hint at other growth factors.
Read more